Quantcast

Latest Oncolytic virus Stories

2011-04-05 01:00:00

SAN FRANCISCO and ILLKIRCH, France, April 5, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that new data from Phase 1 and 2 clinical studies of JX-594 were presented in an oral presentation...

2011-03-24 06:30:00

CALGARY, March 24 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC, NASDAQ: ONCY) today announced that it has completed patient enrollment in its U.S. Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. "This study was performed in part to confirm the results of our UK Phase II study, which enrolled a slightly different patient population, and to...

2011-03-14 16:14:32

The research points to a clear strategy for identifying the subset of liver cancer patients who might benefit from treatment with a therapeutic monoclonal antibody In a research study appearing in the journal Cancer Cell on March 14, scientists from Cold Spring Harbor Laboratory (CSHL) and four other institutions have identified a strategy for targeted molecular therapy in liver cancer, which currently has limited treatment options and one of the worst one-year survival rates of any cancer...

2011-02-23 06:30:00

CALGARY, Feb. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC) (NASDAQ: ONCY) announced today that enrollment has been completed in a U.K. translational clinical trial investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases (REO 013). The principal investigator is Professor Alan Melcher of St. James's University Hospital and the trial is sponsored by the University...

2011-02-22 06:00:00

SAN FRANCISCO, Feb. 22, 2011 /PRNewswire/ -- Jennerex, Inc. (San Francisco), a clinical-stage cancer biotherapeutics company, today announced the appointment of James M. Burke, M.D. to the newly-created position of vice president, clinical research. Dr. Burke will be responsible for all global clinical research activities related to Jennerex pipeline compounds. "Dr. Burke has been working with Jennerex in an advisory capacity as a clinical advisor for over a year, and has provided...

2011-02-09 03:59:00

HELSINKI, February 9, 2011 /PRNewswire/ -- Oncos Therapeutics, a biotech company developing novel cancer therapeutics based on its next generation oncolytic viruses, announced today the appointment of Dr. Mikael von Euler, MD, PhD, FFPM, as Chief Medical Officer. Earlier this year, the Company announced the appointments of Dr. Jonathan Knowles and Dr. Robert Burns to its Board of Directors. "Oncos has already treated over 200 patients across different solid tumor types with many...

2011-01-19 06:00:00

SAN FRANCISCO, Jan. 19, 2011 /PRNewswire/ -- Jennerex, Inc. (San Francisco), a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today announced the appointment of Ursula Fritsch to the newly-created position of vice president, regulatory affairs. Dr. Fritsch will be responsible for developing global regulatory strategies and managing all aspects of regulatory affairs for all Jennerex pipeline product candidates....

2011-01-13 15:16:21

New research shows that oncolytic viruses, which are engineered to destroy cancer cells, might be more effective in treating deadly brain tumors if equipped with an enzyme that helps them penetrate the tumor. The enzyme, called chondroitinase, helps the cancer-killing virus clear its way through the thickets of protein molecules that fill space between cells and impede the virus's movement through the tumor, say researchers at the Ohio State University Comprehensive Cancer Center-Arthur G....

2010-12-23 18:09:28

The silencing of specific genes of the germinal cell lines reduces brain tumors in flies Scientists at IRB Barcelona have discovered that some brain tumours in larvae of the fruit fly Drosophila melanogaster use the genetic programme of germline cells to grow. The removal of some of these genes leads to healthy brains. This finding demonstrates that these genes are crucial for tumour development. The study, headed by ICREA researcher Cayetano González, is published today in the...

2010-12-16 01:00:00

SAN FRANCISCO and ILLKIRCH, France, Dec. 16, 2010 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that enrollment and treatment of patients in a Phase 1b clinical trial has been initiated to...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related